Last reviewed · How we verify

Intra-tympanic injection of drugs

saad elzayat · Phase 1 active Small molecule

Intra-tympanic injection of drugs is a Small molecule drug developed by saad elzayat. It is currently in Phase 1 development. Also known as: Lidocaine in tinnitus.

At a glance

Generic nameIntra-tympanic injection of drugs
Also known asLidocaine in tinnitus
Sponsorsaad elzayat
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intra-tympanic injection of drugs

What is Intra-tympanic injection of drugs?

Intra-tympanic injection of drugs is a Small molecule drug developed by saad elzayat.

Who makes Intra-tympanic injection of drugs?

Intra-tympanic injection of drugs is developed by saad elzayat (see full saad elzayat pipeline at /company/saad-elzayat).

Is Intra-tympanic injection of drugs also known as anything else?

Intra-tympanic injection of drugs is also known as Lidocaine in tinnitus.

What development phase is Intra-tympanic injection of drugs in?

Intra-tympanic injection of drugs is in Phase 1.

Related